Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization

Abstract Background The efficacy‐effectiveness gap between randomized trial and real‐world evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has been well characterized by previous literature, consistent with initial concerns raised by health technology assessment ag...

Full description

Bibliographic Details
Main Authors: Brandon Lu, Wei Fang Dai, Ruth Croxford, Wanrudee Isaranuwatchai, Jaclyn Beca, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Rebecca E. Mercer, Timothy P. Hanna, Kelvin K. W. Chan
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Cancer Medicine
Subjects:
cost‐effectiveness
ipilimumab
metastatic melanoma
oncology
real‐world evidence
Online Access:https://doi.org/10.1002/cam4.5862

Internet

https://doi.org/10.1002/cam4.5862

Similar Items